Valsartan

also known as Diovan · VAL · VAL489 · D763 · D764 · Diovan (Valsartan) · Diovan is a brand name of Valsartan · V= Valsartan = brand name : Diovan · +1 more

Developed for: hypertensive disorder · essential hypertension · type 2 diabetes mellitus · hyperlipidemia · heart failure · diabetic kidney disease · proteinuria · cardiovascular disorder
+54 more
· chronic kidney disease · diastolic heart failure · atrial fibrillation · congestive heart failure · COVID-19 · hypertensive heart disease · metabolic syndrome X · stroke disorder · heart disorder · HIV infectious disease · ischemic disease · ischemic stroke · myocardial infarction · symptomatic heart failure · systolic heart failure · abdominal aortic aneurysm · acute coronary syndrome · adult acute respiratory distress syndrome · Alport syndrome · aortic valve stenosis · atherosclerosis · atherosclerotic cardiovascular disease · chemotherapy-induced toxicity · chronic transplant rejection · cognitive disorder · coronary artery disorder · coronary microvascular disorder · dilated cardiomyopathy · glucose intolerance · hyperlipidemia, combined, 2 · hypertensive nephropathy · IgA glomerulonephritis · impaired renal function disease · kidney disorder · major depressive disorder · mitral valve insufficiency · non-Hodgkin lymphoma · obesity disorder · pneumonia · prediabetes syndrome · pulmonary arterial hypertension · ST-elevation myocardial infarction · carotid artery disorder · disorder of defective peroxisome oxidative status · focal segmental glomerulosclerosis · hypertrophic cardiomyopathy · immunoglobulin A vasculitis · intracerebral hemorrhage · left ventricular failure · membranous glomerulonephritis · myocardial disorder · nephrosclerosis · resistant hypertension · Tako-tsubo cardiomyopathy
Investigated by: Novartis · Novartis Pharmaceuticals · Boehringer Ingelheim · LG Life Sciences · IlDong Pharmaceutical Co Ltd · Damanhour University
+154 more
· HK inno.N Corporation · Mario Negri Institute for Pharmacological Research · St. Marianna University School of Medicine · Tehran University of Medical Sciences · AJU Pharm Co., Ltd. · Agenzia Italiana del Farmaco · Asan Medical Center · Forest Laboratories · JW Pharmaceutical · Kitasato University · Medical University of Silesia · Myopharm Limited · National Cheng-Kung University Hospital · National Heart, Lung, and Blood Institute (NHLBI) · Radboud University Medical Center · Shanghai Pharmaceuticals Holding Co., Ltd · Shiraz University of Medical Sciences · Stanford University · Tokai University · University Medical Centre Ljubljana · Yuhan Corporation · ARKAY Therapeutics · Ain Shams University · Albany Medical College · Assaf-Harofeh Medical Center · Assistance Publique - Hôpitaux de Paris · Astellas Pharma Inc · Australian and New Zealand Intensive Care Research Centre · Baker Heart and Diabetes Institute · Bayer · Berry Consultants · Bio-innova Co., Ltd · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Canadian Institutes of Health Research (CIHR) · CardioVascular Research Foundation · Chengdu First People's Hospital · Chinese PLA General Hospital · Chipscreen Biosciences, Ltd. · Chong Kun Dang Pharmaceutical · Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań · Daiichi Sankyo · Danish Cardiovascular Research Academy · Danish Heart Foundation · Dazhou Central Hospital · Dong-A ST Co., Ltd. · Dong-A University · EMS · Farma de Colombia SA · Federico II University · Fifth Affiliated Hospital, Sun Yat-Sen University · Flinders University · Fondation IUCPQ · GlaxoSmithKline · Global Coalition for Adaptive Research · Golestan University of Medical sciences · Gruppo di Ricerca GISSI · Guan'an People's Hospital · Gulhane School of Medicine · Göteborg University · Hallym University Medical Center · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · HeartDrug Research LLC · Hospital Aristide Le Dantec, Dakar, Senegal · Hospital Britanico · Hospital Moinhos de Vento · Hospital do Coracao · Institute of Cardiology Abidjan · Intensive Care National Audit & Research Centre · Intermountain Health Care, Inc. · Isfahan University of Medical Sciences · Jiangsu HengRui Medicine Co., Ltd. · Jikei University School of Medicine · Johns Hopkins University · Jonathan Beaudoin · all 160 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed essential hypertension 1 milestone
Filed	China (NMPA)	—	essential hypertension	2026-06-16	“NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS” irasia.com ↗
Approved Indication not stated 3 milestones
Label expansions (5)	US (FDA)	DIOVAN	—	2002-04-05 – 2021-04-19	fda.gov ↗
Approved	EU (EMA)	Dafiro	—	2007-01-15	europa.eu ↗
Approved	US (FDA)	DIOVAN	—	1996-12-23	fda.gov ↗

Trials 225 · started per year

today

US approved 1996

EU approved 2007

199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 127 trials · 2 met primary
Phase 1	NCT07544888	Nov 2025 → Mar 2026	heart disorder, hypertensive disorder	Shaikh Zayed Hospital, Lahore	Completed	No outcome recorded
Phase 1	NCT07331389	Sep 2025 → Jan 2026 overdue	—	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 1	NCT06248112	May → Jun 2024	—	Bio-innova Co., Ltd	Unknown	No outcome recorded
Phase 1	NCT05681273	Feb → Mar 2023	type 2 diabetes mellitus	Chipscreen Biosciences, Ltd.	Completed	No outcome recorded
Phase 1	NCT05259020	Feb → Mar 2022	hyperlipidemia, hypertensive disorder	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 1	NCT05077475	Sep 2021 → Apr 2022	hypertensive disorder	AJU Pharm Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT05077462	Sep 2021 → Apr 2022	hypertensive disorder	AJU Pharm Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT04859452	May → Jul 2021	—	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04185090	Feb → Apr 2020	hyperlipidemia, hypertensive disorder	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 1	NCT03532854	May → Aug 2018	—	LG Chem	Completed	No outcome recorded
Phase 1	NCT02817217	Mar → Jul 2016	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02631031	Nov 2015 → Oct 2016	—	Ain Shams University	Completed	No outcome recorded
Phase 1	NCT02060019	Mar → Jun 2014	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT02069821	Mar 2014	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT01838967	Apr → Jun 2013	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT01918358	Dec 2012 → Jan 2013	hyperlipidemia, hypertensive disorder	LG Life Sciences	Completed	No outcome recorded
Phase 1	NCT01735890	Sep → Nov 2012	—	HK inno.N Corporation	Completed	Met primary
Phase 1	NCT01823913	Jul → Aug 2012	—	Severance Hospital	Completed	Met primary
Phase 1	NCT01609907	Nov 2011 → May 2012	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	No outcome recorded
Phase 1	NCT01918709	Sep → Nov 2011	hyperlipidemia	LG Life Sciences	Completed	No outcome recorded
Phase 1	NCT01447485	Aug → Oct 2011	chronic kidney disease, essential hypertension, nephrotic syndrome	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01232049	Oct 2010 → Mar 2011	—	Asan Medical Center	Completed	No outcome recorded
Phase 1	NCT01115972	Mar → Apr 2010	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00416468	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00416728	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00415883	Jul 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00310778	Mar 2006 → Mar 2007	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT03686657	Dec 2026 → Dec 2030	arthritic joint disease, hypertensive disorder, obesity disorder, type 2 diabetes mellitus	ARKAY Therapeutics	Withdrawn	No outcome recorded
Phase 1/2	NCT05194111	Aug 2022 → Nov 2028 expected	heart failure	Virginia Commonwealth University	Recruiting	No outcome recorded
Phase 213 trials · 1 met primary · 1 missed
Phase 2	NCT07139405	Sep 2026 → Sep 2027 expected	type 2 diabetes mellitus	Myopharm Limited	Not yet recruiting	No outcome recorded
Phase 2	NCT06053580	Feb 2024 → Jul 2027 expected	heart failure, pulmonary arterial hypertension	University of Washington	Recruiting	No outcome recorded
Phase 2	NCT05593575	Mar 2023 → Dec 2024	diabetic kidney disease	Shanghai Pharmaceuticals Holding Co., Ltd	Completed	No outcome recorded
Phase 2	NCT04055428	Aug 2020 → Dec 2026 expected	cardiovascular disorder, diabetes mellitus	University of Alabama at Birmingham	Recruiting	No outcome recorded
Phase 2	NCT04164732	Jan 2020 → Aug 2023	—	Novartis Pharmaceuticals	Completed	Missed primary
Phase 2	NCT01681576	Aug 2012 → Oct 2013	hypertensive disorder	Novartis Pharmaceuticals	Completed	Met primary
Phase 2	NCT01353508	Mar 2011 → Aug 2012	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01281306	Jan → Dec 2011	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01122251	Dec 2009 → May 2010	essential hypertension	LG Life Sciences	Completed	No outcome recorded
Phase 2	NCT00939588	Jul → Dec 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00409578	Feb 2007 → Apr 2009	acute coronary syndrome	Novartis	Completed	No outcome recorded
Phase 2	NCT00294086	Dec 2005 → Jan 2007	heart failure	Novartis	Completed	No outcome recorded
Phase 2	NCT00309257	Jan 2004 → Jun 2008	Alport syndrome	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT07539298	May 2026 → May 2029 expected	mitral valve insufficiency	Jonathan Beaudoin	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03315832	Jan 2023 → Jul 2025	aortic valve stenosis, cardiac valvular defect	University Hospital, Limoges	Withdrawn	No outcome recorded
Phase 2/3	NCT00425373	Nov 2006 → Mar 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 373 trials · 13 met primary · 5 missed
Phase 3	NCT06930885	Jun 2025 → May 2031 expected	atherosclerotic cardiovascular disease	Hospital do Coracao	Recruiting	No outcome recorded
Phase 3	NCT06863987	Feb 2025 → Dec 2027 expected	essential hypertension	Shandong New Time Pharmaceutical Co., LTD	Enrolling by invitation	No outcome recorded
Phase 3	NCT06643819	Oct 2024 → Mar 2026 overdue	essential hypertension	Chong Kun Dang Pharmaceutical	Recruiting	No outcome recorded
Phase 3	NCT05155137	Dec 2021 → Dec 2029 expected	cognitive disorder, stroke disorder	Hospital Moinhos de Vento	Recruiting	No outcome recorded
Phase 3	NCT05359068	Jun 2021 → Dec 2023	essential hypertension	Shanghai Pharmaceuticals Holding Co., Ltd	Completed	Met primary
Phase 3	NCT04591210	Jan 2021 → Dec 2024	COVID-19, cardiovascular disorder	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT04606563	Oct 2020 → Apr 2022	COVID-19	University of British Columbia	Terminated	Missed primary
Phase 3	NCT04128891	Feb 2020	diastolic heart failure	Flinders University	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT02662894	Oct 2019 → Sep 2020	hyperlipidemia, hypertensive disorder	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT03541109	May 2019 → Aug 2023	ST-elevation myocardial infarction	Isfahan University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT03552575	Jul 2018 → Jul 2020	heart failure	NHS Greater Glasgow and Clyde	Completed	Missed primary
Phase 3	NCT03508739	Jun 2018 → Jun 2026	hypertensive disorder, prediabetes syndrome, type 2 diabetes mellitus	University of Pennsylvania	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT03066804	Aug 2017 → Oct 2019	diastolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	Mixed
Phase 3	NCT03459560	Dec 2015 → Mar 2022	cardiovascular disorder	Tehran University of Medical Sciences	Unknown	Met primary
Phase 3	NCT02480764	Aug 2015 → Sep 2017	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT02145104	Jun 2014 → Jun 2016	essential hypertension	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 3	NCT01850160	Apr 2013 → Mar 2015	hypertensive disorder	Farma de Colombia SA	Completed	No outcome recorded
Phase 3	NCT01928628	May 2012 → Apr 2013	essential hypertension	LG Life Sciences	Completed	Met primary
Phase 3	NCT01918332	Apr 2012 → Mar 2013	hyperlipidemia, hypertensive disorder	LG Life Sciences	Completed	No outcome recorded
Phase 3	NCT01508026	Jan 2012 → Mar 2013	hypertensive disorder	Forest Laboratories	Completed	Met primary
Phase 3	NCT01245608	Oct 2011 → Jan 2018	cardiovascular disorder	Tehran University of Medical Sciences	Completed	Missed primary
Phase 3	NCT01365481	Aug 2011 → Sep 2015	chronic kidney disease, hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01415505	Aug 2011 → Jan 2013	essential hypertension	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT01402843	Jun 2011 → Jun 2012	hyperlipidemia, hypertensive disorder	JW Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT01001572	Sep 2009 → May 2010	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00699192	May 2008 → May 2009	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00548067	Sep 2007 → Mar 2008	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00446511	Jun 2007 → Jun 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00494715	May 2007 → Apr 2016	type 2 diabetes mellitus	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 3	NCT00503152	May 2007 → Jul 2016	type 2 diabetes mellitus	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 3	NCT00457626	Apr 2007 → May 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00446563	Mar 2007 → Mar 2010	hypertensive heart disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00435162	Mar 2007 → Jan 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00446524	Feb 2007 → Oct 2008	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00437645	Jan → Nov 2007	essential hypertension	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00433836	Jan 2007 → Feb 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00413049	Jan → Nov 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00386607	Oct 2006 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00392262	Aug 2006 → Feb 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00360178	Jul → Dec 2006	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00353912	Jun 2006 → Apr 2007	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00350168	Jun 2006 → Apr 2007	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00327587	May 2006 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00338936	May 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00327145	Mar 2006 → Jan 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00311740	Mar → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00367939	Dec 2005 → Jul 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00396656	Dec 2005 → Dec 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00394745	Nov 2005 → Jun 2007	essential hypertension, metabolic syndrome X	Novartis	Completed	No outcome recorded
Phase 3	NCT00254475	Nov 2005 → Sep 2006	essential hypertension, hyperlipoproteinemia	Novartis	Completed	Met primary
Phase 3	NCT00273299	Nov 2005 → Jul 2006	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00171015	Dec 2004 → Apr 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00376272	Nov 2004 → Jan 2008	atrial fibrillation	Gruppo di Ricerca GISSI	Completed	No outcome recorded
Phase 3	NCT00171002	Nov 2004 → Jun 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00171535	Oct 2004 → Apr 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00170963	Oct 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00170989	Sep 2004 → Jul 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171093	Sep 2004 → Jan 2006	essential hypertension, hyperlipidemia	Novartis	Completed	No outcome recorded
Phase 3	NCT00171067	Jul 2004 → May 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00170976	Apr 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171080	Apr 2004 → Mar 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00409643	Jan → Jul 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171028	Dec 2003 → Nov 2006	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00241007	Dec 2003 → Mar 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00241137	Sep 2003 → Jan 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00409851	Apr 2003 → Mar 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00409760	Jan 2003 → Feb 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00171041	Dec 2002 → Mar 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00308425	Oct 2002 → Jun 2005	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00385931	Jan 2002 → Apr 2003	hyperlipidemia, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00097786	Jan 2002 → Oct 2009	type 2 diabetes mellitus	Novartis Pharmaceuticals	Completed	Mixed
Phase 3	NCT00089518	—	HIV infectious disease, kidney disorder	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Phase 495 trials · 6 met primary · 6 missed
Phase 4	NCT06501651	Aug 2024 → Apr 2025 overdue	diabetic kidney disease, essential hypertension, type 2 diabetes mellitus	Sichuan Academy of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 4	NCT06035978	Mar 2024 → Apr 2026	symptomatic heart failure	University Hospital Ostrava	Unknown	No outcome recorded
Phase 4	NCT05528419	Feb 2023 → Jan 2026	atrial fibrillation, hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT05487261	Dec 2022 → Feb 2025	heart failure	Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań	Unknown	No outcome recorded
Phase 4	NCT06487949	Dec 2022 → Oct 2023	hypertensive disorder	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT05637853	Oct 2022 → Aug 2024 overdue	symptomatic heart failure	Göteborg University	Active not recruiting	No outcome recorded
Phase 4	NCT05881720	Jan 2022 → Jun 2023	heart failure	Damanhour University	Completed	No outcome recorded
Phase 4	NCT05387967	Jan → Jun 2021	systolic heart failure	National Institute of Cardiovascular Diseases, Pakistan	Completed	No outcome recorded
Phase 4	NCT04335786	Apr 2020 → May 2021	COVID-19, adult acute respiratory distress syndrome, severe acute respiratory syndrome	Radboud University Medical Center	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT04769778	Feb 2020 → Jun 2023	chronic transplant rejection	Josep m Cruzado	Unknown	No outcome recorded
Phase 4	NCT03594825	Nov 2018 → Jun 2023	hypertensive nephropathy	Fifth Affiliated Hospital, Sun Yat-Sen University	Unknown	No outcome recorded
Phase 4	NCT04707508	Dec 2017 → Jan 2019	type 2 diabetes mellitus	Nantou Christian Hospital	Completed	No outcome recorded
Phase 4	NCT01805804	Jan 2017 → Jan 2019	—	Medical University of Silesia	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02973035	Dec 2016 → Jan 2020	hypertensive disorder	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT02690974	Mar 2016 → Jun 2017	systolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02817360	Feb 2016 → Dec 2025 overdue	heart disorder, type 2 diabetes mellitus	Martin Huelsmann	Recruiting	No outcome recorded
Phase 4	NCT02433119	Mar 2015 → Sep 2016	hypertensive disorder	Dong-A ST Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT02299310	Nov 2014 → Nov 2015	chronic kidney disease	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 4	NCT02062645	Feb 2014 → Sep 2015	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01904981	Jan 2014 → Apr 2017	abdominal aortic aneurysm	Yonsei University	Completed	No outcome recorded
Phase 4	NCT02058446	Oct 2013 → Mar 2014	essential hypertension	TSH Biopharm Corporation Limited	Completed	No outcome recorded
Phase 4	NCT01699490	Aug 2012 → Jul 2015	major depressive disorder	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT01541189	Feb 2012 → Jan 2013	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01368536	May 2011 → Feb 2012	hypertensive disorder, type 2 diabetes mellitus	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01030458	Sep 2010 → Mar 2012	hypertensive disorder	KU Leuven	Completed	No outcome recorded
Phase 4	NCT01167153	May 2010 → Apr 2011	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01095822	Mar → Dec 2010	diabetes mellitus	HeartDrug Research LLC	Unknown	No outcome recorded
Phase 4	NCT00931710	Jul 2009 → Jan 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00902304	Jul 2009 → Jul 2011	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01070043	Jun 2009 → Sep 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00927394	May 2009 → Oct 2011	essential hypertension	Novartis	Completed	Met primary
Phase 4	NCT00858299	Mar 2009 → Dec 2011	chronic kidney disease, proteinuria	Samsung Medical Center	Unknown	No outcome recorded
Phase 4	NCT01241487	Feb 2009 → Jan 2011	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00809926	Jan → Jul 2009	hypertensive disorder	Novartis	Completed	Missed primary
Phase 4	NCT00874601	Oct 2008 → Jul 2011	ischemic stroke	Hallym University Medical Center	Unknown	No outcome recorded
Phase 4	NCT00716950	Jul 2008 → Feb 2009	essential hypertension	University of Pavia	Unknown	No outcome recorded
Phase 4	NCT00698646	Apr 2008 → Jun 2009	essential hypertension	Novartis Pharmaceuticals	Completed	Missed primary
Phase 4	NCT00687206	Mar → May 2008	erectile dysfunction, hypertensive disorder	Federico II University	Completed	No outcome recorded
Phase 4	NCT00921570	Feb 2008 → May 2009	hypertensive disorder, proteinuria, type 2 diabetes mellitus	Gulhane School of Medicine	Completed	No outcome recorded
Phase 4	NCT00687973	Jan 2008 → Jan 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01340326	Nov 2007 → Dec 2014	myocardial infarction	Dong-A University	Completed	No outcome recorded
Phase 4	NCT00700271	Oct 2007 → Aug 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01400256	Aug 2007 → Feb 2009	ischemic stroke	Stanford University	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT00457483	Aug 2007 → Dec 2010	essential hypertension	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT00550095	Jun 2007 → Nov 2009	proteinuria	Novartis	Completed	No outcome recorded
Phase 4	NCT00409487	Dec 2006	hypertensive disorder, obstructive sleep apnea syndrome	University Hospital, Grenoble	Completed	Met primary
Phase 4	NCT00425997	Dec 2006 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00439738	Dec 2006 → Nov 2007	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01425411	Nov 2006 → Nov 2008	hypertensive disorder, hypertensive heart disease	Mustafa Kemal University	Completed	No outcome recorded
Phase 4	NCT00426478	Nov 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00523549	Nov 2006 → Jan 2008	hypertensive disorder	Novartis Pharmaceuticals	Completed	Missed primary
Phase 4	NCT00407680	Oct 2006 → Mar 2009	hypertensive disorder, type 2 diabetes mellitus	Kitasato University	Unknown	No outcome recorded
Phase 4	NCT00589732	Sep 2006 → Dec 2009	coronary artery disorder	CardioVascular Research Foundation	Completed	No outcome recorded
Phase 4	NCT00400777	Aug 2006 → Nov 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00460213	Jul 2006 → Dec 2008	hypertensive disorder	Kitakyushu-Tsuyazaki Hospital	Completed	No outcome recorded
Phase 4	NCT00351130	Jun 2006 → Mar 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00304226	Feb 2006 → Jan 2007	hypertensive disorder	Novartis	Completed	Met primary
Phase 4	NCT00280540	Dec 2005 → Aug 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00277472	Nov 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00168779	Sep 2005 → Jul 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00821574	Jul 2005 → Mar 2007	hyperlipidemia, combined, 2	Novartis	Completed	No outcome recorded
Phase 4	NCT00171600	Jul 2005 → Jan 2007	diabetic kidney disease, hypertensive disorder	Novartis	Terminated	No outcome recorded
Phase 4	NCT00200694	Mar 2005 → Mar 2007	proteinuria	Nantes University Hospital	Terminated	No outcome recorded
Phase 4	NCT01917149	Mar 2005 → Jul 2013	dilated cardiomyopathy	Xijing Hospital	Completed	Met primary
Phase 4	NCT00343499	Nov 2004 → Jul 2007	atrial fibrillation	Intermountain Health Care, Inc.	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00171574	Nov 2004 → Jul 2006	diabetic kidney disease, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00170937	Nov 2004 → Mar 2006	hypertensive disorder, metabolic syndrome X	Novartis	Completed	Missed primary
Phase 4	NCT00185055	Nov 2004 → Feb 2005	—	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00171132	Aug 2004 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00170924	Aug 2004 → Jun 2006	diastolic heart failure, hypertensive disorder	Novartis	Completed	Missed primary
Phase 4	NCT00171327	Jul 2004 → Sep 2005	hyperlipidemia, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171353	Jul 2004 → Sep 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171756	Jun 2004 → Mar 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00162955	May 2004 → Sep 2010	non-Hodgkin lymphoma	Osaka City University	Completed	No outcome recorded
Phase 4	NCT00241124	Apr 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00333489	Mar 2004 → Apr 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00171782	Feb → Dec 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171119	Jan 2004 → Mar 2005	diabetic kidney disease, hypertensive disorder	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT00149227	Jan 2004 → Jan 2009	congestive heart failure, hypertensive disorder, ischemic disease, stroke disorder	Kyoto Prefectural University of Medicine	Completed	Met primary
Phase 4	NCT00154271	Jan 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00202618	Dec 2003 → Jun 2006	diabetes mellitus, hypertensive disorder, proteinuria	Shiga University	Unknown	No outcome recorded
Phase 4	NCT00171054	Sep 2003 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00240448	Sep 2003 → Jun 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00241098	May 2003 → Jun 2005	congestive heart failure, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00153023	Apr 2003 → Dec 2005	diabetic kidney disease, essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171561	Mar 2003 → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00190580	Feb 2003 → Apr 2008	chronic kidney disease, hypertensive disorder	KVT-Study Group	Completed	No outcome recorded
Phase 4	NCT00239538	Jan 2003 → Dec 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171106	Dec 2002 → Aug 2007	diastolic heart failure	Novartis	Completed	Missed primary
Phase 4	NCT00241085	Nov 2002 → Aug 2005	hypertensive disorder, proteinuria, type 2 diabetes mellitus	Novartis	Completed	No outcome recorded
Phase 4	NCT00241150	Nov 2002 → Jan 2005	hypertensive disorder, metabolic syndrome X	Novartis	Completed	No outcome recorded
Phase 4	NCT00241072	Sep 2002 → Jul 2005	glucose intolerance, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00133328	Jan 2002 → Nov 2005	congestive heart failure, hypertensive disorder, ischemic disease	Jikei University School of Medicine	Unknown	Met primary
Phase 4	NCT00034840	Oct 2001 → Aug 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00367562	Jan 1996 → Dec 2005	IgA glomerulonephritis	Hospital Britanico	Completed	No outcome recorded

Phase not applicable12 trials · 1 met primary
—	NCT05892146	May 2021 → Dec 2025	breast cancer, chemotherapy-induced toxicity, heart failure, lymphoma	National Cheng-Kung University Hospital	Unknown	No outcome recorded
—	NCT03393377	Sep 2014 → Jun 2015	atherosclerosis	University Medical Centre Ljubljana	Completed	No outcome recorded
—	NCT02606279	Jul 2014 → Aug 2016	HIV infectious disease, muscular atrophy, premature aging syndrome	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Enrollment
—	NCT03309618	Nov 2012 → Nov 2013	myocardial infarction	University Medical Centre Ljubljana	Completed	No outcome recorded
—	NCT01767298	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT01767259	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT00732966	Sep 2008 → Sep 2009	hypertensive disorder	Assaf-Harofeh Medical Center	Unknown	No outcome recorded
—	NCT00721773	Sep 2008 → Oct 2014	impaired renal function disease	Sun Yat-sen University	Completed	No outcome recorded
—	NCT00627991	Aug 2007 → ?	stroke disorder	Stanford University	Withdrawn	No outcome recorded
—	NCT00424801	Jan 2007 → Dec 2008	coronary microvascular disorder, essential hypertension	University of Aarhus	Terminated	No outcome recorded
—	NCT00518479	Sep 2003 → Apr 2004	hypertensive disorder, hypertensive heart disease	University of Leeds	Completed	No outcome recorded
—	NCT00530595	—	cardiovascular disorder	Saitama Medical University	Completed	Met primary

Comparator or background therapy131 trials
Phase 0	NCT04623866 Comparator	Nov 2020 → Aug 2021	immunoglobulin A vasculitis	The Children's Hospital of Zhejiang University School of Medicine	Unknown	No outcome recorded
Phase 1	NCT07444398 Background	Jan → Mar 2026 overdue	symptomatic heart failure	Khawaja Danish Ali	Recruiting	No outcome recorded
Phase 1	NCT04047940 Comparator	Nov 2019 → Feb 2020	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT03012763 Comparator	Apr 2016 → Jan 2017	—	University Medicine Greifswald	Completed	No outcome recorded
Phase 1	NCT03009474 Comparator	Feb → Apr 2015	hyperlipidemia, hypertensive disorder	HK inno.N Corporation	Completed	No outcome recorded
Show all 131 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 19

Date	Issuer	Release
2026-08-27	Myopharm Limited	Results Myopharm Reports Preliminary Findings from TriGlytza® Type 1 Diabetes Pilot Study myopharm.com ↗ After 15 days of treatment, TriGlytza® treated animals demonstrated a statistically significant 25% reduction in non-fasting blood glucose measured four hours after morning dosing, compared with STZ-vehicle animals.
2026-06-16	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS) irasia.com ↗
2025-08-06	Myopharm Limited	Results TriGlytza® achieves significant reduction in HbA1c % in Pre-Clinical Type 2 Diabetes myopharm.com ↗ Myopharm Limited, is pleased to announce positive significant efficacy data on the key endpoint of HbA1c % in its pre- clinical trial of TriGlytza® for the treatment of Type 2 Diabetes Mellitus (T2DM).
2024-09-20	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL
2024-07-23	Zydus Lifesciences Limited	Regulatory Zydus receives final approval from USFDA for Valsartan Tablets zyduslife.com ↗ Zydus Lifesciences Limited (including its subsidiaries/ affiliates , hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg (USRLD: Diovan® tablets).
2023-08-24	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Regulatory VOLUNTARY ANNOUNCEMENT - SACUBITRIL VALSARTAN SODIUM TABLETS OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ The board of directors (the “Board”) of the CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Sacubitril Valsartan Sodium Tablets (50mg, 100mg, 200mg) (the “Product”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.
2020-06-29	Novartis Pharmaceuticals	Regulatory Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options novartis.com ↗
2019-11-17	Novartis Pharmaceuticals	Results Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF novartis.com ↗ The data suggest that, in specific subgroups, treatment with Entresto may result in greater reductions in heart failure hospitalizations and cardiovascular death, as compared to valsartan.
2019-07-29	Novartis Pharmaceuticals	Results Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) novartis.com ↗ Novartis today announced topline results from the global Phase III PARAGON-HF study, investigating the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients[1].
2019-03-16	Zydus Lifesciences Limited	Regulatory Zydus receives final approval from the USFDA for Valsartan and Hydrochlorothiazide Tablets zyduslife.com ↗ Zydus Cadila has received the final approval from the USFDA to market Valsartan and Hydrochlorothiazide Tablets USP (US RLD – Diovan HCT Tablets) in the strengths of 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg.
2018-04-04	Novartis Pharmaceuticals	Results Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril novartis.com ↗ Post-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to those taking enalapril
2017-11-12	Novartis Pharmaceuticals	Results New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure novartis.com ↗ Entresto significantly reduced levels of NT-proBNP, a key blood marker associated with cardiovascular risk in patients with heart failure; the magnitude of the decrease was similar to that observed in the PARADIGM-HF study[1]
2016-06-22	Novartis Pharmaceuticals	Results Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology novartis.com ↗
2016-04-02	Novartis Pharmaceuticals	Results New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless... novartis.com ↗ Novartis announced today new analyses of the data from PARADIGM-HF showing that Entresto (TM) (sacubitril/valsartan) consistently demonstrated benefit among heart failure patients with reduced ejection fraction (HFrEF), even when patients are considered clinically stable and regardless of background therapy.[1],[2]
2015-11-24	Novartis Pharmaceuticals	Regulatory Novartis' heart failure medicine Entresto(TM) receives EU approval novartis.com ↗ Novartis announced today that the European Commission (EC) has approved Entresto TM (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
2015-09-18	Novartis Pharmaceuticals	Regulatory Swissmedic approves Novartis' new heart failure medicine Entresto(TM) novartis.com ↗ Novartis announced today that Swissmedic has approved Entresto(TM) (sacubitril/valsartan), previously known as LCZ696, to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF).
2015-01-06	Lupin Limited	Regulatory Lupin launches Generic DIOVAN® Tablets lupin.com ↗ having received final approval from the United States Food and Drug Administration (FDA).
2015-01-06	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Launches Generic Diovan® in the United States tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the Food and Drug Administration (FDA) approval and the launch of the generic equivalent to Diovan® (Valsartan) Tablets in the United States.
2008-06-12	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Tentative Approval of Generic Diovan® Tablets tevapharm.com ↗

All press releases naming this drug 20 releases

Date	Issuer	Release
2026-08-27	Myopharm Limited	Myopharm Reports Preliminary Findings from TriGlytza® Type 1 Diabetes Pilot Study myopharm.com ↗
2026-06-16	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS) irasia.com ↗
2025-08-06	Myopharm Limited	TriGlytza® achieves significant reduction in HbA1c % in Pre-Clinical Type 2 Diabetes myopharm.com ↗
2024-09-20	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - VALSARTAN LEVOAMLODIPINE MALEATE TABLETS OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
2024-07-23	Zydus Lifesciences Limited	Zydus receives final approval from USFDA for Valsartan Tablets zyduslife.com ↗
2023-08-24	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	VOLUNTARY ANNOUNCEMENT - SACUBITRIL VALSARTAN SODIUM TABLETS OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
2020-06-29	Novartis Pharmaceuticals	Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options novartis.com ↗
2019-11-17	Novartis Pharmaceuticals	Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF novartis.com ↗
2019-07-29	Novartis Pharmaceuticals	Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF) novartis.com ↗
2019-03-16	Zydus Lifesciences Limited	Zydus receives final approval from the USFDA for Valsartan and Hydrochlorothiazide Tablets zyduslife.com ↗
2018-08-25	Novartis Pharmaceuticals	Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗
2018-04-04	Novartis Pharmaceuticals	Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril novartis.com ↗
2017-11-12	Novartis Pharmaceuticals	New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure novartis.com ↗
2016-06-22	Novartis Pharmaceuticals	Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology novartis.com ↗
2016-04-02	Novartis Pharmaceuticals	New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless... novartis.com ↗
2015-11-24	Novartis Pharmaceuticals	Novartis' heart failure medicine Entresto(TM) receives EU approval novartis.com ↗
2015-09-18	Novartis Pharmaceuticals	Swissmedic approves Novartis' new heart failure medicine Entresto(TM) novartis.com ↗
2015-01-06	Lupin Limited	Lupin launches Generic DIOVAN® Tablets lupin.com ↗
2015-01-06	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches Generic Diovan® in the United States tevapharm.com ↗
2008-06-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval of Generic Diovan® Tablets tevapharm.com ↗

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 363 sources stand behind the page.

Field	Value	Cited text
Known as	Valsartan	“Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗ 353 “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily” NCT01271985 ↗ “Fixed-dose combination tablet containing valsartan 160 mg and amlodipine 10 mg. Orally administered once daily for 6 weeks during Treatment Period 2.” NCT07116863 ↗ “500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.” NCT03686657 ↗ “RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)” NCT03502031 ↗ “If the patient is intolerant to either of these, an angiotensin receptor blocker (ARB)(Candesartan, Losartan, Valsartan) will be introduced.” NCT05637853 ↗ “The polypill comprises hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg.” PMID 32894967 ↗ Aug 2020 “Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together” NCT05077462 ↗ Show 343 more sources
Known as	D763	“1 D763(Valsartan 80 mg)” NCT06643819 ↗
Known as	D764	“1 D764(Valsartan 160 mg)” NCT06643819 ↗
Known as	Diovan	“The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day...” NCT00874601 ↗ 7 “Valsartan (Diovan), an FDA approved angiotensin-II receptor antagonist (blocker) clinically indicated for the treatment of essential hypertension” NCT01095822 ↗ “Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months” NCT01129557 ↗ “MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan)” NCT00034840 ↗ “Drug: Diovan (Valsartan)” NCT00993109 ↗ “Valsartan (Diovan)” NCT04335786 ↗ NCT07547878 ↗ NCT01518855 ↗
Known as	Diovan (Valsartan)	“Diovan (Valsartan)” NCT01432106 ↗
Known as	Diovan is a brand name of Valsartan	“Diovan is a brand name of Valsartan” NCT00208767 ↗
Known as	V= Valsartan = brand name : Diovan	“V= Valsartan = brand name : Diovan” NCT01918709 ↗
Known as	VAL	“OBJECTIVE: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ)...” PMID 23721363 ↗ Jul 2013 5 “To compare this ARB with another in the class, the authors studied the effects of AZL-M and valsartan (VAL) in 984 patients with primary hypertension in a randomized,...” PMID 21762358 ↗ Jun 2011 “treatment with sacubitril/valsartan (Sac/Val) was associated with greater reduction in NT-proBNP than valsartan (Val) alone in patients stabilized after an episode of worsening...” PMID 40268180 ↗ Apr 2025 “We compared an angiotensin receptor blocker (valsartan; VAL), a beta-blocker (nebivolol; NEB) and the combination of NEB/VAL” PMID 26116459 ↗ Mar 2015 “valsartan (VAL)/HCTZ 80/12.5 mg” PMID 18761785 ↗ Aug 2008 “valsartan (Val) 80 mg” PMID 18538118 ↗ Jun 2008
Known as	VAL489	“Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the...” NCT02924727 ↗ 2 “Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.” NCT04912167 ↗ “Valsartan (VAL489)” NCT01447485 ↗
Known as	valsartan (Diovan)	“valsartan (Diovan)” NCT00000620 ↗
Action	Inhibit	“angiotensin II receptor blocker (ARB), valsartan” PMID 24035165 ↗ Sep 2013
Route	Oral	“Diovan® (Valsartan 160 mg p.o. Once Daily)” NCT00034840 ↗